Cell and Gene Therapies (CGTs) represent some of the most innovative and promising advancements in modern medicine. However, the complexity of their development, combined with an evolving regulatory environment, presents significant challenges. For developers seeking investment for their product development, early and informed regulatory input is crucial to mitigating risks and increasing confidence in the product’s pathway to market. 

This white paper highlights the critical role of regulatory affairs in the early stages of Cell and Gene Therapy (CGT) development, focusing on how a robust regulatory strategy can be a powerful tool for securing investment. Key areas explored include the value of integrating regulatory planning into investor pitches, the importance of demonstrating a clear regulatory pathway, and the role of consultants specialised in CGTs. These insights underscore how early regulatory input, when leveraged effectively, can reduce uncertainty and enhance the attractiveness of a CGT development project to investors.